Literature DB >> 17270241

Conventional renal cancer in a patient with fumarate hydratase mutation.

Heli J Lehtonen1, Ignacio Blanco, Jose M Piulats, Riitta Herva, Virpi Launonen, Lauri A Aaltonen.   

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumor predisposition syndrome caused by mutations in the fumarate hydratase (FH) gene. HLRCC is characterized by uterine and cutaneous leiomyomas, renal cell cancer, and uterine leiomyosarcoma. Typically, renal cell cancers in HLRCC are unilateral and display a papillary type 2 or ductal histology. We describe here a 23-year-old patient carrying a novel FH mutation (N330S) with a bilateral renal cell center. Carcinoma of the right kidney showed papillary structure, but the left tumor was diagnosed as a conventional (clear cell) renal carcinoma, a type not previously described in HLRCC. The clear cell renal carcinoma also displayed loss of the normal FH allele and the FH immunostaining. Our finding extends the number of cases in which HLRCC can be suspected, and the FH immunohistochemistry may serve as a useful tool to screen for HLRCC in young individuals with clear cell renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17270241     DOI: 10.1016/j.humpath.2006.10.011

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

Review 1.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 2.  Mitochondrial determinants of cancer health disparities.

Authors:  Aaheli Roy Choudhury; Keshav K Singh
Journal:  Semin Cancer Biol       Date:  2017-05-06       Impact factor: 15.707

Review 3.  Revisiting the TCA cycle: signaling to tumor formation.

Authors:  Nuno Raimundo; Bora E Baysal; Gerald S Shadel
Journal:  Trends Mol Med       Date:  2011-07-20       Impact factor: 11.951

4.  Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome.

Authors:  Victoria M Raymond; Casey M Herron; Thomas J Giordano; Stephen B Gruber
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

Review 5.  Misdiagnosis of clear cell renal cell carcinoma.

Authors:  Vladimir A Valera; Maria J Merino
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

Review 6.  Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC).

Authors:  Mei Hua Wong; Chuen Seng Tan; Soo Chin Lee; Yvonne Yong; Aik Seng Ooi; Joanne Ngeow; Min Han Tan
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

7.  No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.

Authors:  Pia Vahteristo; Taru A Koski; Laura Näätsaari; Maija Kiuru; Auli Karhu; Riitta Herva; Satu-Leena Sallinen; Outi Vierimaa; Erik Björck; Stéphane Richard; Betty Gardie; Didier Bessis; Emmanuel Van Glabeke; Ignacio Blanco; Richard Houlston; Leigha Senter; Marja Hietala; Kristiina Aittomäki; Lauri A Aaltonen; Virpi Launonen; Rainer Lehtonen
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 8.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.

Authors:  Fred H Menko; Eamonn R Maher; Laura S Schmidt; Lindsay A Middelton; Kristiina Aittomäki; Ian Tomlinson; Stéphane Richard; W Marston Linehan
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

9.  Hemangioblastoma in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: a phenotypic overlap between VHL and HLRCC Syndromes.

Authors:  Eryn Dow; Ingrid M Winship
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

10.  Hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a rapid autopsy report of metastatic renal cell carcinoma.

Authors:  Aaron M Udager; Ajjai Alva; Ying-Bei Chen; Javed Siddiqui; Amir Lagstein; Satish K Tickoo; Victor E Reuter; Arul M Chinnaiyian; Rohit Mehra
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.